Abstract
The alkylating agent cyclophosphamide has been used in the treatment of multiple myeloma for over 60 years. At low doses, cyclophosphamide also has significant immunomodulatory activity, which can be used to modify the immunosuppressive tumor microenvironment in order to augment responses to existing therapies. Immune-mediated therapies are becoming more widespread in modern approaches to myeloma treatment. In this review, we discuss the effects cyclophosphamide has on the immune system, and how it can be used synergistically with other treatment modalities including the immunomodulatory agents, monoclonal antibodies and cellular therapies.
| Original language | English (Ireland) |
|---|---|
| Media of output | Published abstracts |
| Publisher | LIPPINCOTT WILLIAMS & WILKINS |
| ISBN (Print) | 2572-9241 |
| ISBN (Electronic) | 2572-9241 |
| DOIs | |
| Publication status | Published - 1 Apr 2020 |